ipilimumab,nivolumab,tremelimumab,durvalumab,Sorafenib
bms,AstraZeneca,Pfizer
['nivo', 'check,mate,040', '/ipi']
 the long-term survival follow-up of the checkmate-040 study (arm a), the 5-year survival of the patients receiving nivo/ipili combo therapy is 29% (though small sample size, wide 95% ci). 
Reborn. 原ID @whyes . 肝脏外科医生，特别关注肝癌治疗进展。
谢绝将 **所有** 推文转载到其他网站。
@whyes@m.cmx.im